Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus chemoradiotherapy in nasal cavity and paranasal sinus cancer
NCT05114707Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2021
- Primary completion
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in nasal cavity cancer, Paranasal Sinus Cancer (NPSC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
nasal cavity cancerParanasal Sinus Cancer (NPSC)
Beyond the preview
Go deeper on NCT05114707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05114707.